Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Fluticasone Furoate/Vilanterol on Arterial Stiffness in COPD
NCT01336608Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2011
- Primary completion
- Nov 2014
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Fluticasone Furoate/Vilanterol, Vilanterol and Placebo (3 arms). Primary endpoint: Mean Change From Baseline in Aortic Pulse Wave Velocity at 24 weeks. Started Mar 2011; status: completed.
02
Drugs
fluticasonevilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01336608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01336608.